SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Decorative border of fly different flavor ice cream cones in waffle - white, pink, brown with chocolate sauce on pink.
Mergers & acquisitions
Pharma Double-Dippers Lead Q1 Deal Activity to Nearly $47B
Deal-hungry Big Pharmas, a long-sought biotech prize, an infrequent buyer and one serial biotech rabblerouser highlight a busy quarter in biopharma M&A.
April 1, 2026
 · 
1 min read
 · 
Annalee Armstrong
Businessman in starting position ready to sprint run stock illustration
Mergers & acquisitions
Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy
In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in multiple Phase 3 trials.
March 31, 2026
 · 
4 min read
 · 
Annalee Armstrong
Illustration showing a downward graph trend
Rare diseases
PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease
PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect gene splicing, but the biotech attributed the poor result to an outlier.
March 31, 2026
 · 
2 min read
 · 
Heather McKenzie
Red alarm clock on dollar banknotes. Retro style alarm clock and dollars. Time to work / tome to make money concept.
Mergers & acquisitions
Lilly Wakes Up Sleep Market With $6.3B Centessa Buy To Challenge Takeda
In the buyout, Eli Lilly picks up Centessa Pharmaceuticals’ lead asset cleminorexton, which could go toe-to-toe with Takeda’s oveporexton, currently under FDA review with a decision expected in the third quarter.
March 31, 2026
 · 
2 min read
 · 
Tristan Manalac
Orlando, Florida
Immunology and inflammation
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases
Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of next-generation skin drugs but also shed light on how they might fare on the market.
March 31, 2026
 · 
4 min read
 · 
Tristan Manalac
Stagflation, economic slow down or recession while inflation high up, GDP growth decrease causing by unemployment concept, fearful businessman riding fall down economic graph with inflation high up.
Immunology and inflammation
Viridian Turns Red as Thyroid Eye Disease Data Disappoint
Despite hitting its primary endpoint, Viridian’s thyroid eye disease antibody failed to ease eye bulging to the degree that analysts had been hoping for, and the biotech’s stock price fell by one-third.
March 31, 2026
 · 
2 min read
 · 
Tristan Manalac
ransparent plastic tube being blocked by orange balls on blue background. Illustration of the concept of digestive disorders and difficulties on career paths
Cardiovascular disease
Merck’s Cholesterol Pill Delivers ‘Antibody-Like Efficacy’ After Earning FDA Voucher
Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner’s National Priority Voucher.
March 31, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration of businessman running back around
Mergers & acquisitions
After Missing Kezar Buyout in 2024, Tang Returns as CEO of Aurinia With $50M Offer
Serial biotech investor Kevin Tang previously unsuccessfully tried to buy Kezar Life Sciences via Concentra Biosciences, a biotech consolidation company owned by the venture capital firm he runs.
March 30, 2026
 · 
2 min read
 · 
Annalee Armstrong
command failed. Business team walk in a line following faulty orders vector
Layoffs
Takeda Restructuring Could Push More Than 600 US Staffers Out of Jobs
Takeda’s layoffs include cutting 247 people in Massachusetts. The workforce reduction is meant to help offset investments in areas including a product launch for oral drug candidate zasocitinib, for which the pharma today announced positive Phase 3 data.
March 30, 2026
 · 
2 min read
 · 
Angela Gabriel
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS